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Abstract The high affinity receptor for human IgE (FcORI) on
tissue mast cells and blood basophils is responsible for immediate
hypersensitivity reactions. Binding of human IgE (hIgE) to
FcORI has been shown to be mediated via three independent
regions in the extracellular part of the K-subunit of FcORI
(ecFcORIK). By site-directed mutagenesis we investigated the
contribution of amino acids within the ecFcORIK FG loop
(residues Lys154^Leu165) to binding to hIgE and two monoclonal
anti-FcORIK antibodies (15/1, 5H5/F8). The mutated receptors
were expressed and secreted from eukaryotic cells as amino-
terminal fusion to HSA. We show that the proposed loop region
contributes partly to hIgE binding and that the epitope of mAb
15/1, which inhibits hIgE/FcORIK interaction, maps to this region
whereby a single W156A mutation results in complete loss of
mAb 15/1 binding. In contrast, hIgE binding is not affected by
the W156A mutation indicating that different amino acid
residues within the loop are recognized by the mAbs 15/1 and
hIgE. MAb 5H5/F8 does not recognize a receptor mutant
truncated to Ile170. By screening a random dodecapeptide library
displayed on bacterial flagella the epitope for mAb 5H5/F8 was
mapped to P173REKY177 whereas one of the 15/1 binding clones
displayed a peptide with an amino acid sequence homologous to
Leu158^Ile167. Based on the epitopes identified for the inhibitory
mAb 15/1 and the non-inhibitory mAb 5H5F8 and on binding
data obtained with polyclonal antisera raised against two
ecFcORIK peptides, we propose a structural element in the
membrane proximal part of ecFcORIK which forms a 3D
structure which might facilitate specific and efficient attachment
of hIgE.
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1. Introduction
The binding of IgE to the high a⁄nity FcO receptor (FcORI)
on mast cells and basophils is mediated by the K-subunit of
the tetrameric receptor complex (for review see [1]). The L-
chain and the disul¢de-linked Q-chains appear to function pri-
marily in signal transduction [2]. For high a⁄nity binding of
hIgE (KD = 10310) the extracellular portion of the FcORIK
subunit (ecFcORIK) is su⁄cient [3] which consists of two Ig-
like domains: K(1), membrane-distal, and K(2), membrane-
proximal. Although in humans IgE binding to FcORIK is
mediated via the K(2) domain, high a⁄nity binding is only
achieved in the presence of K(1) [4]. In contrast to hIgE where
single amino acid residues within the CO3 region have been
identi¢ed to be involved in receptor binding [5,6], the binding
site on the receptor is less well characterized (for review see
[7]). According to an existing homology-based 3D model [8],
each of the regions postulated by Hulett et al. [9] to be in-
volved in hIgE binding contains a surface-exposed loop con-
necting anti-parallel L-strands. Several lines of evidence sug-
gest that the C-CP-F-G face of the K(2) domain is involved in
the hIgE/FcORIK interaction (reviewed in [1]). A synthetic
cyclized C-CP peptide mimic (Ile119^Tyr129) was shown to in-
hibit IgE binding to FcORIK [10]. Recently, Cook et al. [11]
demonstrated that a K117D mutation in the C strand reduced
the a⁄nity for IgE by a factor of 30. Mapping of Ab speci¢c
epitopes on a receptor protein or its ligand has been used as
an experimental approach to characterize amino acid regions
involved in the ligand-receptor interaction [12,13]. MAbs
against FcORIK have also been used as tools to identify
stretches of the K(2) domain which are assumed to take part
in hIgE binding; e.g. inhibitory mAb 15A5 [14] binds to a
peptide corresponding to Gly100^Val115 in K(2). Another in-
hibitory mAb, 15/1, has been described as a neutralizing anti-
body in various investigations [15,16].
In this report, the contribution of amino acid residues with-
in the FG loop to hIgE binding and their allocation to epit-
opes recognized by monoclonal anti-FcORIK Abs 15/1 and
5H5/F8 was investigated.
2. Materials and methods
2.1. Materials
ecFcORIK was produced in insect cells and puri¢ed at Novartis
Basle. FcORIK-speci¢c mAb 15/1 [15] was obtained from J.-P. Kinet,
Harvard Medical School, Boston, MA. The anti-ecFcORIK mAb
5H5F8 has been described [17]; rabbit polyclonal anti-FcORIK anti-
serum was produced at Novartis Vienna and human IgE was obtained
from B. Stadler, University Bern.
2.2. Cyanogen bromide cleavage of ecFcORIK
100 Wg ecFcORK was subjected to cyanogen bromide cleavage [18]
and products were separated by HPLC. Elution was performed on a
0.1% tri£uoroacetic acid/acetonitrile gradient. The fragment Gly100^
Leu179, containing K(2), was isolated and used in ELISA to test for
binding of hIgE and mAb.
2.3. Endoproteinase Arg-C cleavage of ecFcORIK
100 Wg ecFcORIK was diluted 1:1 with 2Uincubation bu¡er (200
mM Tris-HCl, pH 7.6, 20 mM CaCl2) and incubated with endopro-
teinase Arg-C (Boehringer Mannheim) according to the manufactur-
er’s protocol. The reaction was brought to pH 3.0 with 25% tri£uoro-
acetic acid and separated by reversed phase chromatography
(Beckman model 126). Elution was performed with an increasing tri-
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£uoroacetic acid gradient (5^70%). Eluted peak fractions were lyophi-
lized and tested in ELISA for binding to hIgE and to mAbs. Amino
acid analysis was carried out with 0.5^1 nmol peptide hydrolyzed in
vapor phase (at 110‡C for 24 h) with 6 M HCl containing 0.1%
phenol. The amino acid composition of this mixture was determined
with an LKB 2131 Alpha Plus instrument.
2.4. Mutagenesis
Receptor mutants were expressed in COS-7 cells as amino-terminal
fusion to HSA (HSA-ecFcORIK). 5U106 cells were electroporated
with 30 Wg DNA with a Bio-Rad Gene Pulser (250 WF, 400 V),
then transferred to a 80 cm2 culture £ask (Nunc) with 25 ml medium
(DMEM H21, 10% fetal calf serum, 1% penicillin/streptomycin, 1% L-
glutamine) and incubated for 72 h at 37‡C with 5% CO2.
Two unique HindIII restriction sites were introduced in FcORIK by
PCR by mutating nucleotides a643g, g644c, g646t and c679g, a680c
(sequence according to [19]) which resulted in the amino acid changes
V155L and N166K, I167L (numbering according to [20]). Mutants
were generated using splice overlap extension PCR with HindIII site
£anked primers (bold). Mutant 1 (HindIII cassette, HSA-ecFcORIK
Val1^I1e170, V155L, N166K, I167L) forward: 5P TCA TAC TAG
TGA ATT CAC CAT GAA GTG GGT AAC C 3P, reverse: 5P
CCT CGA GGT GAA TTC TTA TCA TAT TAC AGT AAG
CTT GAG GGG CTC AGA CTC ATA GTC CAG CTG CCA
AAG CTT GCC CGT ACA GTA GTA GG 3P. Mutant 3 (FcQRII)
forward: 5P CAC TGC ACA GGA AAG CTT GGC TAC ACG CTG
TTC TCA TCC AAG CC 3P, reverse: 5P CAC TTG GAC AGT AAG
CTT CAC AGG CTT GGA TGA GAA CAG CG 3P. Mutant 4
(S162A) forward: 5P CAC TGC ACA GGA AAG CTT TGG CAG
CTG GAC TAT GAG GCC GAG CCC 3P, reverse: 5P CAG TTG
GAC AGT AAG CTT GAG GGG CTC GGC CTC ATA GTC CAG
CTG CCA 3P. Mutant 5 (Q157A, S162A) forward: 5P CAC TGC
ACA GGA AAG CTT TGG GCT CTG GAC TAT GAG GCT
GAG CCC 3P, reverse: 5P CAG TTG GAC AGT AAG CTT GAG
GGG CTC AGC CTC ATA GTC CAG AGC CC 3P. Mutant 6
(W156A, D159A, E161A, E163A) forward: 5P CAC TGC ACA
GGA AAG CTT GCC CAG CTG GCT TAT GCT TCT GCT
CCC 3P, reverse: 5P CAG TTG GAC AGT AAG CTT GAG GGG
AGC AGA AGC ATA AGC CAG CTG GGC 3P. Mutant 7
(W156A, Y160A) forward: 5P CAC TGC ACA AAG CTT GCC
CAG CTG GAC GCT GAG TCT GAG CCC 3P, reverse: 5P CAG
TTG GAC AGT AAG CTT GAG GGG CTC AGA CTC AGC GTC
CAG CTG GGC 3P. Mutant 8 (W156A) forward: 5P CAC TGC ACA
GGA AAG CTT GCC CAG CTG GAC TAT GAG TCT GAG CCC
3P, reverse: 5P CAG TTG GAC AGT AAG CTT GAG GGG CTC
AGC CTC ATA GTC CAG CTG GGC 3P. PCR fragments were
HindIII digested and ligated in the HindIII cut expression cassette
of mutant 1. Mutant 2 (loop deletion) was created by cutting plasmid
DNA encoding mutant 1 with HindIII and religation. Each mutant
receptor DNA sequence was con¢rmed by double-stranded dideoxy
sequencing [21].
2.5. Concentration determination of receptors in cell supernatants
(ELISA)
100 Wl of a solution containing 5 Wg/ml rabbit polyclonal anti-HSA
(Cappel, Durham, NC) in a bu¡er containing 0.1 M NaHCO3, 0.01%
NaN3, pH 9.6, were immobilized in Strip Plate-8 wells (Costar, Cam-
bridge, MA) in a humidi¢ed chamber at 4‡C overnight. After washing
twice with 300 Wl PBS (150 mM NaCl, 3 mM KCl, 8 mM Na2HPO4,
1.5 mM K2PO4, pH 7.5) containing 0.05% Tween 20 (PBST) pH 7.2,
100 Wl of COS supernatants was added and incubated for 2 h at room
temperature. The wells were washed twice with 300 Wl PBST and
incubated with 100 Wl of a goat anti-human HSA-horseradish peroxi-
dase (HRP) conjugate (Cappel, 1:1000 diluted in PBST, 2% FCS) for
90 min at room temperature. Plates were washed and subsequently
incubated with 100 Wl of ABTS (Bio-Rad) substrate. The reaction was
stopped after 5 min with 100 Wl of 3% oxalic acid and absorbance at
405 nm was read. The readouts were corrected for unspeci¢c binding
assayed with supernatants of mock-transfected cells. The concentra-
tion was determined using an HSA-standard calibration curve; all
samples were assayed in triplicates. Binding of receptor mutants to
immobilized mAb and hIgE was tested as described before with 200
ng mAb (15/1, 5H5/F8) or 240 ng hIgE were immobilized instead of
the polyclonal anti-HSA conjugate.
2.6. Epitope mapping of mAb 5H5/F8 and 15/1
The pFliTrx random peptide library (Invitrogen, San Diego, CA)
panning procedure and colony blot analysis were exactly performed
following the protocol of Lu et al. [22]. MAbs bound to colonies in
dot blot experiments were incubated with goat anti-mouse IgG con-
jugated to HRP (Bio-Rad) and developed with the ECL kit (Amer-
sham).
2.7. Production and puri¢cation of rabbit antisera
Polyclonal sera were raised in rabbits against the keyhole limpet
hemocyanin (KLH) coupled peptides N166ITVI170 and E161SEPL-
NITVIKAPRE175. Sera were tested in ELISA for binding to ecFcOR-
IK and for their ability to inhibit hIgE/FcORIK interaction, and puri-
¢ed with the AvidChrom Protein A Antibody Puri¢cation Kit (Sig-
ma). The obtained IgG preparation was a⁄nity puri¢ed using the
peptide coupled to activated CH Sepharose 4B (Pharmacia) proce-
dure.
2.8. Binding of anti-peptide antisera to immobilized ecFcORIK
(ELISA)
Strip Plate-8 wells (Costar) were incubated at 4‡C overnight with
100 ng ecFcORIK in 100 Wl coating bu¡er (0.1 M NaHCO3, 0.01%
NaN3, pH 9.6) in a humidi¢ed chamber. After blocking, wells were
incubated in duplicate with 2, 4 and 8 Wg/well of each a⁄nity puri¢ed
anti-peptide antiserum for 2 h at room temperature and subsequently
with a goat anti-rabbit IgG HRP conjugate (Bio-Rad) for 1 h at room
temperature. The wells were washed three times with PBST and fur-
ther incubated with 100 Wl of the ABTS substrate (Bio-Rad). The
reaction was stopped with 100 Wl of 2% oxalic acid and color inten-
sities were read at 405 nm.
2.9. Competition ELISA
1 ng biotinylated ecFcORIK was preincubated with 0.15, 1, 5, 10 Wg/
well antisera in 100 Wl reaction volume ^ all samples were assayed in
triplicate. The mixtures were incubated at 4‡C overnight and subse-
quently 1 h at 25‡C. Then the samples were transferred to microtiter
plate wells each coated with 150 ng hIgE. After a 2 h incubation the
wells were washed as described and incubated with 100 Wl of a 1:1000
dilution of streptavidin conjugated to alkaline phosphatase (Gibco)
for 1 h at 25‡C. Wells were developed with the Alkaline Phosphatase
Substrate Kit (Bio-Rad).
3. Results and discussion
The experiments shown in this report focused on assessing
the contribution of the FG loop of the extracellular region of
FcORIK (ecFcORIK) to hIgE binding. Insight into the struc-
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Table 1
Binding of Igs to ecFcORIK fragments generated by chemical or protease cleavage (ELISA)
Cleavage Fragment isolated Recognition of fragment by
pc.-a serum human IgE mAb 15/1 mAb 5H5/F8
BrCN Glu99^Leu179 +++ 3 3 ++
Arg-C/1 Tyr129^Lys154 +++ 3 3 3
Arg-C/2 Val155^Lys171 +++ 3 3 3
Arg-C/3 Val118^Lys128 3 3 3 3
Arg-C/4 Asn112^Lys176 +++ 3 3 ++
++ indicates binding 10-fold over background and 2-fold lower than the reference polyclonal antiserum (pc.-a +++).
A. Nechansky et al./FEBS Letters 441 (1998) 225^230226
tural characteristics was gained by identi¢cation of epitopes
within this region recognized by mAb raised against ecFcORIK
and by polyclonal anti-peptide antisera. In a ¢rst study re-
combinant ecFcORIK was cleaved with Arg-C protease or
cyanogen bromide and the fragments were probed for binding
to hIgE and various antibodies (Table 1). The experiments
revealed the antigenicity of the carboxy terminal segment
Val155^Lys171, comprising the FG loop, since this region was
recognized by a polyclonal anti-ecFcORIK antiserum. In con-
trast, it was found to be able to bind to neither hIgE nor the
mAbs tested. The inhibitory mAb 15/1, which is expected to
recognize a conformational epitope sensitive to denaturation
[16], did not bind to ecFcORIK fragments generated by pro-
tease digestion or chemical cleavage. Under the denaturing
chemical conditions applied by cyanogen bromide cleavage
also hIgE was not able to bind to fragment Glu99^Leu179
representing K(2). MAb 5H5/F8 has been shown to detect
ecFcORIK in Western blots from SDS-PAGE run under dena-
turing conditions [17] and is therefore assumed to recognize a
stable epitope. The Ab binding pattern obtained for 5H5/F8
points towards recognition of amino acids between Lys176 and
Leu179.
Hulett et al. [9] demonstrated that each of three independ-
ent ecFcORIK regions transfers IgE binding capability to a
receptor chimera when transplanted into the homologous
site of the low a⁄nity IgG receptor (FcQRII). Each of the
three regions contains a loop according to an existing homol-
ogy-based 3D model [8].
We focused on the inspection of the membrane proximal
FG loop, e.g. by site speci¢c mutagenesis, because: (i) prelimi-
nary data suggested that mAb 5H5/F8 recognizes an epitope
in the carboxy-terminal part of ecFcORIK ; (ii) we wanted to
evaluate the contribution of the FG loop which is part of the
‘Hulett fragment’ Ser146^Val169 to IgE binding; and (iii) indi-
cations exist that binding of the non-inhibitory mAb 15/1 is
mediated via this region (unpublished data).
For mutagenesis, a recombinant construct was prepared
which is shown in Fig. 1. To facilitate linker mutagenesis by
cassette cloning two HindIII restrictions sites were introduced
resulting in amino acid changes V155L and N166K, I167L
(mutant 1). Receptor mutants were transiently expressed in
COS-7 cells as amino terminal fusion to HSA. The HSA
part has no in£uence on the IgE binding capability of FcORIK
and was used for quantitation of secreted receptor in COS cell
supernatants and, more importantly, as a tag for measuring
relative binding intensities to the various Abs since this tag
remains una¡ected by the mutations made in the ecFcORIK
part. Binding of hIgE and mAb 15/1 to mutant 1 was reduced
as compared to HSA-ecFcORIK (Table 2). Because Hulett et
al. [8] showed that truncation of FcORIK to amino acid Val169
does not interfere with hIgE binding, we argue that the re-
duced binding of mutant 1 is due to the exchange of the
indicated amino acids (V155L, N166K, and I167L), preferen-
tially N166K resulting in the replacement of a polar residue
by a charged one. In agreement with the results of the enzy-
matic cleavage experiments mAb 5H5/F8 failed to bind to
mutant 1 indicating that this non-inhibitory mAb recognizes
an epitope beyond Ile170. Deletion of the loop region Trp156^
Leu167 (mutant 2) abolished binding to both hIgE and mAb
15/1, probably due to severe structural disturbances. Replace-
ment of this region with the homologous FcQRIIK sequence
(mutant 3) partly restored hIgE binding capacity while mAb
15/1 did not recognize this mutant indicating that an essential
part of the 15/1 epitope resides within Trp156^Leu167. In con-
trast, hIgE binding seems to be only in part mediated via this
region. This is in accordance with published data [9] suggest-
ing three independent FcORIK regions capable of mediating
hIgE binding when transplanted into the homologous sites of
FcQRIIK.
Alanine substitution mutagenesis was used to further char-
acterize FcORIK derived amino acids residing within the FG
loop region Trp156^Leu165 important for hIgE and mAb 15/1
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Fig. 1. HSA-ecFcORIK expression construct for mutagenesis (upper lane). In mutant 1 (bottom lane), two unique HindIII restriction sites £ank-
ing the DNA sequence encoding the FG loop were introduced and the carboxy-terminal end was truncated to Ile170.
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binding. Substitution by alanine deletes all interactions made
by atoms beyond the L-carbon and should reveal the contri-
bution by the removed side chain to the binding reaction [12].
The choice of amino acids to be substituted within the FG
loop was based on inspection of the ecFcORIK model that can
be obtained from the Brookhaven Protein Data Bank (Code
1ALT) and on a publication evaluating amino acid preferen-
ces at protein binding sites [23]. As can be seen from the
binding pattern shown in Table 2, Ser162 (mutant 4) is critical
for hIgE and mAb 15/1 binding. The additional Q157A ex-
change in mutant 5 completely abolished binding to both
molecules. Serine residue 162 seems to be of structural impor-
tance because it is highly conserved among Fc receptors sug-
gesting a pivotal role in building up the overall K(2) structure.
While for hIgE no other important residue was identi¢ed
within the FcORIK region Trp156^Leu167, residue Trp156 was
found to be essential for mAb 15/1 binding whereas hIgE
binding remained una¡ected by the mutating Trp156 as dem-
onstrated with mutants 6, 7 and 8. Since the yields of mutant
proteins generated by transient COS cell expression was too
low to allow physico-chemical characterization, e.g. CD spec-
troscopy, binding to hIgE was taken as indicative of correct
folding. Therefore, we argue that the loss of mAb 15/1 bind-
ing is not due to a structural rearrangement caused by the
W156A mutation but is indeed dependent on the removal of
the tryptophan side chain. This is in agreement with Sechi et
al. [24] who speculated that aromatic amino acids might be
part of the mAb 15/1 epitope. Moreover, a modeling study of
K(2) [25] showed that in both association modes that were
examined, several tryptophans are still accessible to solvent.
Furthermore, tryptophans occur more frequently within pro-
tein binding sites than other amino acid residues [23].
To con¢rm the alanine substitution mutagenesis data ob-
tained with mAb 15/1 and to identify the epitope of mAb
5H5/F8, the FliTrx random peptide library was screened.
This library displays random peptides on the surface of Es-
cherichia coli on the major bacterial £agellar protein [22].
Screening of the FliTrx library by panning on mAb 15/1
(Fig. 2A) resulted in the identi¢cation of binding clones that
support the mutagenesis results : one peptide sequence identi-
¢ed (15-8) shows partial sequence homology with the FG
loop. Most of the peptide sequences displayed by the other
clones contain a tryptophan residue. Only one of these clones
(15-7) reacted in Western blot with mAb 15/1 (data not
shown). Parts of its sequence (polar/positively charged/hydro-
phobic/tryptophan) can be aligned to FcORIK region
S153LVW156 based on amino acid properties. The importance
of this region for mAb 15/1 binding is further stressed by the
reduced binding observed with mutant 1.
Screening the FliTrx library with mAb 5H5/F8 revealed a
core consensus sequence of the peptides displayed by the bind-
ing clones which maps to position Pro173^Tyr177 of FcORIK
(Fig. 2B) explaining its inability to bind to mutant 1 truncated
to Ile170. This is also in accordance with the results obtained
with proteolytically cleaved ecFcORIK where binding was ob-
served to fragments Gln100^Leu179 and to Asn112^Lys176 but
not to Val155^Lys171. Moreover, these data might explain why
mAb 5H5/F8 is not able to bind to FcORIK expressed on
monocytic cells (G. Mudde, personal communication): the
vicinity of the cell membrane might render its epitope inacces-
sible to cell-bound K-chain.
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Table 2
Receptor composition and correlation with Ig binding (ELISA)
COS-7 cell expressed ecFcORIK amino acid sequence Binding to
IgE 15/1 5H5/F8
HSA ecFcORIK K154VWQLDYESEPLNITVIKAPREKYWL179 +++ +++ +++
HSA mutant 1 K154LWQLDYESEPLKLTVI170 ++ + 3
HSA mutant 2 K154L9999TVI170 3 3 3
HSA mutant 3 K154LGYTLFSSKPVKLTVI170 + 3 3
HSA mutant 4 K154LWQLDYEAEPLKLTVI170 3 + n.d.
HSA mutant 5 K154LWALDYEAEPLKLTVI170 3 3 n.d.
HSA mutant 6 K154LAQLAYASAPLKLTVI170 ++ 3 n.d.
HSA mutant 7 K154LAQLDAESEPLKLTVI170 ++ 3 n.d.
HSA mutant 8 K154LAQLDYESEPLKLTVI170 ++ 3 n.d
Mutated residues in ecFcORIK are underlined. For comparison of HSA ecFcORIK with HSA mutant 1, 100% is de¢ned as binding of HSA
ecFcORIK to hIgE; +++ = 75%, ++ = 55%, + = 35%, 3= 10%. Binding of subsequent mutants is set in relation to HSA mutant 1 which is then
de¢ned as 100% in an analogous way.
Fig. 2. Peptide sequences identi¢ed by screening the FliTrx random
peptide library with (A) mAb 15/1 and (B) mAb 5H5/F8. Shaded
amino acids belong to a consensus sequence that can be aligned by
similar amino acid properties to the ecFcORIK sequence whereas
amino acids typed bold represent identities.
A. Nechansky et al./FEBS Letters 441 (1998) 225^230228
The most striking result of the cleavage and mutagenesis
experiments was the observation that the epitopes recognized
by mAbs 15/1 and 5H5/F8 were found to lie in close vicinity
to each other, not only by the primary amino acid sequence of
K(2) but also as deduced from the three-dimensional model
(Fig. 3). Despite this obvious closeness, the two mAb display
quite contrary biological activities: 15/1 e⁄ciently inhibits
hIgE binding whereas 5H5/F8 is non-inhibitory. Therefore,
these epitopes must by structurally separated in FcORIK in a
way that hIgE binding is blocked after mAb 15/1 binding, but
is still possible after mAb 5H5/F8 binding. Additionally, 15/1
does not compete with 5H5/F8 for receptor binding (data not
shown) indicating that their epitopes are not overlapping.
Taking into account that there is no steric hindrance for
hIgE binding by mAb 5H5/F8 bound to the receptor, it is
reasonable to propose a model where the two Ab epitopes
are separated due to the tertiary structure of FcORIK, e.g.
by a ‘bend’.
Support for this hypothesis was gained by the generation of
polyclonal rabbit antisera against the K-chain peptides
E161SEPLNITVIKAPRE175 and N166ITVI170. The ¢rst se-
quence was chosen because it ful¢lls the following criteria:
(i) it links the two mAb epitopes, (ii) the amino-terminal
part is assumed to have a well de¢ned structure containing
the highly conserved serine residue Ser162 as shown in Fig. 5,
(iii) the sequence has a high probability to be surface exposed
(secondary structure prediction data according to a Chou-
Fasman algorithm, data not shown) and ^ according to ala-
nine scanning mutagenesis results ^ is part of the 15/1 epitope.
The short peptide was selected to assess the importance of the
NITVI sequence since our data strongly suggested this region
to be involved in mAb 15/1 and hIgE binding. For rabbit
immunization both peptides were chemically coupled to
KLH. Immune sera were pre-puri¢ed over a protein A col-
umn and the obtained IgG fractions were further puri¢ed by
a⁄nity chromatography using the peptide coupled to a Se-
pharose matrix. Both puri¢ed polyclonal anti-peptide Ig frac-
tions recognized ecFcORIK in ELISA (data not shown) and
inhibited the hIgE/ecFcORIK interaction in a concentration
dependent manner (Fig. 4). We therefore propose the exist-
ence of a turn or a bend in the receptor structure within
Glu161^Glu175. Such a bend would not only explain the un-
published ¢ndings that 5H5/F8 does not recognize cell-bound
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Fig. 4. Inhibition of ecFcORIK binding to hIgE by puri¢ed polyclo-
nal anti-ecFcORIK antisera (ELISA). Reduced ecFcORIK binding
was calculated as %, relative to 100% binding obtained with pre-im-
mune serum and shown as % inhibition.
Fig. 3. Brookhaven Protein Data Bank (Code 1ALT) homology-based model of ecFcORIK (Val1^Ala172). The K(1) domain is shown in the
background whereas K(2) is drawn in a way that incorporates the results of this report. The NITVI amino acid stretch is colored green and
the receptor amino acid sequence is schematically elongated up to Leu179.
A. Nechansky et al./FEBS Letters 441 (1998) 225^230 229
FcORIK whereas 15/1 strongly binds to the receptor expressed
on various cell types, but might also provide a model for the
e⁄cient presentation of the complex high a⁄nity binding re-
gion within the membrane-proximal domain of FcORIK to its
ligand IgE. Homology alignment (Fig. 5) revealed that this
region is well conserved among various Fc receptors and may
therefore represent a general structural element to guarantee
the exposition of binding residues which lie near to the cell
membrane thus allowing access and exact positioning for spe-
ci¢c and e⁄cient attachment of their respective ligands.
Future studies carried out with recombinant receptor mu-
tants expressed on the cell surface will provide more insight
into the structural importance of this stretch of a few amino
acids and help to ¢nd out whether it might represent a target
for the design of agents which inhibit binding of hIgE to its
high a⁄nity receptor.
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Fig. 5. Alignment of amino acid sequences of Fc receptor K-subunits of various species (based on [25]). Numbering is sequential, ranging from
Cys151 to Leu179, and based on the sequence of human FcORIK. The mAb 5H5/F8 epitope is indicated. For mAb 15/1 binding, Trp156 was
found to be essential by mutagenesis experiments. Panning the FliTrx random peptide library with mAb 15/1 identi¢ed clones with amino acid
homology to Leu158^Ile167 (underlined). Residue Ser162 is completely conserved over the receptors. The sequences related to FcORIK NITVI are
shaded.
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